First human test for new drug in people with liver problems
NCT ID NCT07324616
Summary
This early study aims to understand how a new oral drug, EDG-7500, behaves in the body of people with different levels of liver function. It will compare blood levels and safety in 32 adults with mild or moderate liver impairment to those with normal liver function. The goal is to gather basic information to guide future research, not to treat a specific disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT (HI) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The University of Miami Division of Clinical Pharmacology
Miami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.